146533-43-9

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)is used as a pharmaceutical intermediate for the development of new drugs. Its unique chemical properties and structure make it suitable for the synthesis of various drug candidates, particularly in the treatment of diseases such as cancer, viral infections, and neurological disorders. Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-'s potential to modulate biological pathways and target specific enzymes or receptors contributes to its value in drug discovery and development.
Used in Agriculture:
In the agricultural industry, Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)is used as an agrochemical intermediate for the development of new pesticides and herbicides. Its specific chemical properties allow it to target and control pests and weeds effectively, contributing to increased crop yields and reduced crop damage. Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-'s potential to be incorporated into environmentally friendly and sustainable agrochemical formulations further enhances its value in this industry.
Used in Materials Science:
Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)is used in materials science for the synthesis of advanced materials such as polymers and supramolecular structures. Its unique chemical properties and structure make it suitable for the development of materials with specific properties, such as high thermal stability, electrical conductivity, or optical properties. These materials can be used in various applications, including electronics, sensors, and energy storage devices, contributing to technological advancements and innovation in the materials science field.

Upstream product

• 329923-71-9 5-(p-tolyl)-4,6-dihydroxy-pyrimidine 
• 146533-42-8 5-p-tolyl-4,6-(1H,5H)-pyrimidinedione 
• 29148-27-4 diethyl 2-(4-methylphenyl)propane-1,3-dioate 
• 14062-19-2 p-tolylacetic acid ethyl ester 
• 622-47-9 4-tolylacetic acid 

Downstream Products

• 169677-44-5 4-chloro-6-(2-hydroxyethoxy)-5-(4-methylphenyl)pyrimidine 
• 926008-70-0 [4-(6-chloro-5-(p-tolyl)pyrimidin-4-ylethynyl)phenyl]dimethylamine 
• 394204-83-2 2-phenyl-ethenesulfonic acid(6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide 
• 394204-88-7 2-thiophen-2-yl-ethenesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide 
• 169677-57-0 5-(4-methylphenyl)-4,6-dichloro-2-(thien-2-yl)pyrimidine 
• 169677-74-1 4-amino-6-chloro-5-(4-methyl-phenyl)pyrimidine 
• 1393813-58-5 C₂₄H₂₃BrN₆O₄S 
• 245118-94-9 N-(6-chloro-5-(4-methylphenyl)-4-pyrimidinyl)-4-(2-hydroxy-1,1-dimethylethyl)benzenesulfonamide 
• 405307-98-4 2-phenyl-ethanesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide 
• 169677-19-4 4-amino-6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(4-methylphenyl)pyrimidine 
• 169677-45-6 4-azido-6-(2-hydroxyethoxy)-5-(4-methylphenyl)pyrimidine 
• 169677-36-5 4-amino-6-(2-hydroxyethoxy)-5-(4-methylphenyl)pyrimidine 

Relevant academic research and scientific papers

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

Arylalkane-sulfonamides having endothelin-antagonist activity

The invention relates to novel aryl-alkane-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Novel arylethene-sulfonamides

The invention relates to novel aryl-ethene-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Sulfonamides and uses

Sulfonamides of formula I, in which the symbols R1 -R6, X, Y and n have the significance given in the description and which are in part novel compounds, and salts thereof, which can be used as active ingredients for the manufacture of medicaments for the treatment of circulatory disorders, especially hypertension, ischemia, vasospasms and angina pectoris, are described.